Pharmacogenetics of hormone replacement therapy for climacteric symptoms. 2008

Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
Department of Molecular Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, 2-3-10 Kanda-surugadai, Chiyoda-ku, Tokyo 101-0062, Japan.

Hormone replacement therapy (HRT) is highly effective for women suffering from climacteric symptoms, with occasionally severe side effects. To determine which women needs HRT for climacteric symptoms indeed, pharmacogenetical approach for HRT was performed. Under the condition of minimal HRT, 33 patients required HRT for more than 1 year and the remaining 156 did not. Three single nucleotide polymorphisms (SNPs) in estrogen receptor alpha (ERalpha) gene and 3 SNPs and a microsatellite polymorphism in estrogen receptor beta (ERbeta) gene were analyzed using LightTyper and PCR. Homozygous for 18 CA repeats of D14S1026 (OR 8.00, 95% CI 2.56-25.02, P<0.001) and rs1256049 (OR 6.35, 95% CI 2.38-16.92, P=0.004) in ERbeta associated with minimal HRT. In contrast, rs1271572 in 789bp upstream region of ERbeta (OR 0.30, 95% CI 0.14-0.65, P=0.002) gene decreased HRT. rs2228480 in ERalpha gene also increased HRT. Tailored decisions can be expected on the future use of HRT referring genetic polymorphisms of individuals.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D010597 Pharmacogenetics A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION). Pharmacogenomics
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015914 Estrogen Replacement Therapy The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy. Hormone Replacement Therapy, Post-Menopausal,Postmenopausal Hormone Replacement Therapy,Replacement Therapy, Estrogen,Estrogen Progestin Combination Therapy,Estrogen Progestin Replacement Therapy,Estrogen Replacement,Replacement, Estrogen,Therapy, Estrogen Replacement,Estrogen Replacement Therapies,Estrogen Replacements,Hormone Replacement Therapy, Post Menopausal,Replacement Therapies, Estrogen,Replacements, Estrogen,Therapies, Estrogen Replacement
D047628 Estrogen Receptor alpha One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA. ERalpha,Estradiol Receptor alpha,Estrogen Receptor 1,Estrogen Receptors alpha,Receptor alpha, Estrogen,Receptor alpha, Estradiol,alpha, Estradiol Receptor
D047629 Estrogen Receptor beta One of the ESTROGEN RECEPTORS that has greater affinity for ISOFLAVONES than ESTROGEN RECEPTOR ALPHA does. There is great sequence homology with ER alpha in the DNA-binding domain but not in the ligand binding and hinge domains. ERbeta,ERbetacx,Estrogen Receptor 2,Estrogen Receptors beta,Receptor beta, Estrogen

Related Publications

Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
November 1987, Maturitas,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
January 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
January 1995, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
April 2000, Acta obstetricia et gynecologica Scandinavica,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
January 1997, Vestnik Rossiiskoi akademii meditsinskikh nauk,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
February 2024, Journal of the Chinese Medical Association : JCMA,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
March 2006, Journal of cosmetic dermatology,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
February 2014, International journal of cosmetic science,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
February 1991, Vardfacket,
Chikari Takeo, and Kanako Ugai, and Jungo Araki, and Ling Zhang, and Masanori Baba, and Wataru Ohashi, and Koichi Ueno, and Yoichi Suzuki, and Keiko Amano, and Aizan Hirai, and Masaaki Muramatsu
January 1995, Akusherstvo i ginekologiia,
Copied contents to your clipboard!